Imipenem
FDA-approved product (powder, intravenous).
- Registered studies
- 50+
- Lab records
- 505
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Endocarditis
- Infection
- Pneumonia
- Sepsis
- Urinary tract infection
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Carbapenems
- Anti-infective classification
- Classified as an existing antimicrobial.WHO ATC J01DH51
Repurposing investigation
Imipenem is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.
AI-predicted activity
AI prediction · nothing measured- MRSA62.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- E. coli97.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- K. pneumoniae96.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- M. tuberculosis31.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
- MRSA: measured active in 44 of 77 lab records
- E. coli: measured active in 86 of 94 lab records
- K. pneumoniae: measured active in 247 of 334 lab records
Show the latest 150 of 505 laboratory records, with sources
Loading records…
Every record is in ChEMBL, linked above. “Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Imipenem with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Levocabastine HydrochlorideExisting use: Eye allergy, Nasal congestion49.5% AI-predicted activityagainst E. coli5 registered studies
- SaquinavirExisting use: HIV infection, HIV-1 infection, Viral disease49.4% AI-predicted activityagainst E. coli50+ registered studies
- Ibrexafungerp CitrateExisting use: Vulvovaginal candidiasis49.4% AI-predicted activityagainst E. coliNo documented evidence found
- Mobocertinib SuccinateExisting use: Neoplasm, Non-small cell lung carcinoma49.2% AI-predicted activityagainst E. coliNo documented evidence found
- SparsentanExisting use: IGA glomerulonephritis49.2% AI-predicted activityagainst E. coli11 registered studies
- Epinastine HydrochlorideExisting use: Allergic conjunctivitis, Allergic disease, Eye allergy49.0% AI-predicted activityagainst E. coli10 registered studies
- Omidenepag IsopropylExisting use: Ocular hypertension, Open-angle glaucoma49.0% AI-predicted activityagainst E. coli1 registered study
- LesinuradExisting use: Gout, Hyperuricemia49.0% AI-predicted activityagainst E. coli22 registered studies
- Imatinib MesylateExisting use: Acute lymphoblastic leukemia, B-cell acute lymphoblastic leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive and 7 more48.9% AI-predicted activityagainst E. coli50+ registered studies
- Prucalopride SuccinateExisting use: Constipation, Constipation disorder48.9% AI-predicted activityagainst E. coli7 registered studies
- FamciclovirExisting use: Eye infection, Genital herpes, Herpes Labialis and 3 more48.8% AI-predicted activityagainst E. coli25 registered studies
- AbemaciclibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 3 more48.7% AI-predicted activityagainst E. coli50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
A De-Escalating Strategy for Antibiotic Treatment of Pneumonia in The Medical Intensive Care Unit (0787B-092)
NCT00445094 · start 2006-11
Registered record
- Registry ID
- NCT00445094
- Conditions
- Infection; Pneumonia
- Interventions
- MK0787B, imipenem/cilastatin sodium / Duration of Treatment: 7 Days; Comparator: amikacin / Duration of Treatment: 3 Days; Comparator: tazocin / Duration of Treatment: 3 Days; Comparator: vancomycin / Duration of Treatment: 3 Days
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2006-11
- Completion
- 2007-01
- Enrolment
- 120
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionInfection; PneumoniaInterventionMK0787B, imipenem/cilastatin sodium / Duration of Treatment: 7 Days; Comparator: amikacin / Duration of Treatment: 3 Days; Comparator: tazocin / Duration of Treatment: 3 Days; Comparator: vancomycin / Duration of Treatment: 3 DaysPhasePhase 4Registry statusCompletedStudy Comparing Tigecycline and Imipenem/Cilastatin in Chinese Subjects With Complicated Intra-Abdominal Infections
NCT00136201 · start 2005-11
Registered record
- Registry ID
- NCT00136201
- Conditions
- Abdominal Abscess
- Interventions
- tigecycline
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2005-11
- Completion
- 2006-12
- Enrolment
- 200
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAbdominal AbscessInterventiontigecyclinePhasePhase 3Registry statusCompletedComplicated Skin and Skin Structure Infections
NCT00619710 · start 2001-02
Registered record
- Registry ID
- NCT00619710
- Conditions
- Skin Infection; Abscess; Cellulitis
- Interventions
- Meropenem; Imipenem-cilastatin
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2001-02
- Completion
- 2004-04
- Enrolment
- 1,000
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSkin Infection; Abscess; CellulitisInterventionMeropenem; Imipenem-cilastatinPhasePhase 3Registry statusCompletedA Study of the Safety and Effectiveness of Levofloxacin Compared With Imipenem/Cilastatin in Patients With Pneumonia Acquired During Hospitalization
NCT00236834 · start 1997-12
Registered record
- Registry ID
- NCT00236834
- Conditions
- Nosocomial Pneumonia
- Interventions
- levofloxacin; imipenem/cilastitin
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 1997-12
- Completion
- 2001-06
- Enrolment
- 438
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionNosocomial PneumoniaInterventionlevofloxacin; imipenem/cilastitinPhasePhase 3Registry statusCompletedDirect E-test on Bronchoalveolar Lavage From Patients With Ventilator-acquired Pneumonia
NCT01042353
Registered record
- Registry ID
- NCT01042353
- Conditions
- Ventilator Acquired Pneumonia
- Interventions
- E test; standard culture method
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- Not recorded
- Completion
- Not recorded
- Enrolment
- 20
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionVentilator Acquired PneumoniaInterventionE test; standard culture methodPhasePhase 4Registry statusCompleted